EP Patent

EP3266456B1 — Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer

Assigned to Ipsen Biopharm Ltd · Expires 2021-05-05 · 5y expired

What this patent protects

Patent listed against Camptosar.

Drugs covered by this patent

Patent Metadata

Patent number
EP3266456B1
Jurisdiction
EP
Classification
—
Expires
2021-05-05
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Biopharm Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.